Cross Country Healthcare (CCRN)
(Delayed Data from NSDQ)
$14.53 USD
-0.43 (-2.87%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $14.54 +0.01 (0.07%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
CCRN 14.53 -0.43(-2.87%)
Will CCRN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CCRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CCRN
Cross Country (CCRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Cross Country Healthcare (CCRN) Lags Q2 Earnings Estimates
CCRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About Cross Country Healthcare (CCRN) Stock We Don't?
Compared to Estimates, Cross Country (CCRN) Q1 Earnings: A Look at Key Metrics
New Strong Sell Stocks for February 27th
Other News for CCRN
Cross Country CEO Recognized Among Most Loved Workplace Leaders by Newsweek
Cross Country Named Most Loved Workplace? for 2024
Cross Country Healthcare to Attend the Morgan Stanley 22nd Annual Global Healthcare Conference and the 17th Annual Barrington Research Virtual Fall Investment Conference
Buy Rating Affirmed for Cross Country Healthcare Amidst Resilient Q2 Performance and Strategic Growth Potential
Cross Country Healthcare (CCRN) Receives a Rating Update from a Top Analyst